诱导治疗后 CD8 + CD28 - 调节性 T 细胞预测骨髓瘤患者无进展生存期 : GMMG - HD6 多中心 III 期研究结果.
Mesh : Humans Multiple Myeloma / mortality immunology drug therapy pathology CD28 Antigens T-Lymphocytes, Regulatory / immunology Prognosis Progression-Free Survival Induction Chemotherapy Antineoplastic Combined Chemotherapy Protocols / therapeutic use CD8-Positive T-Lymphocytes / immunology Survival Rate Male
来 源:
DOI:10.1038/s41375-024-02290-y
PDF(Pubmed)